Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease
A review makes the case that combination therapy — layering drugs that act on distinct disease mechanisms — is becoming the new standard of care for chronic kidney disease, with each agent providing additive kidney and cardiovascular protection largely independent of the others.
Background
CKD progression is driven by multiple distinct pathways — intraglomerular pressure, inflammation and fibrosis, and immune activation — so single-drug approaches address only part of the problem. The review synthesizes the rationale and evidence for combining therapies that each target a different mechanism.
Key points
For type 2 diabetes with CKD, a growing toolkit reduces kidney failure and cardiovascular events: renin-angiotensin system blockade, SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP-1 receptor agonists. Trial data indicate each works effectively regardless of background medications, and combining them can also mitigate side effects of individual drugs (for example, SGLT2 inhibitors offsetting the hyperkalemia risk of MRAs). Benefits are increasingly extending to non-diabetic CKD, with endothelin receptor antagonists and disease-specific agents (e.g., for IgA nephropathy) emerging.
Clinical implications
Rather than sequential single-agent escalation, clinicians should move toward early, mechanism-complementary combination therapy to maximize kidney and cardiovascular protection. Remaining questions about optimal sequencing, timing, and combinations in non-diabetic CKD are being addressed by ongoing trials.
Category
Transplant
Source
Nephrology Dialysis Transplantation
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.